New NASH drug candidate BAR502 enters first human safety trial

NCT ID NCT06705998

Recruiting now Knowledge-focused Sponsor: BAR Pharmaceuticals s.r.l. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple doses of BAR502 or a placebo. This early-stage trial does not aim to treat NASH but to gather essential safety data for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAR502 (oral tablet)
What this could lead to: If successful, this early study could pave the way for future trials of BAR502 as a potential treatment for NASH (a liver disease).
What could go wrong: This is a very early Phase 1 trial in only 52 healthy people, not patients. It primarily checks safety, not whether the drug works for NASH. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH

Contacts and locations

Locations

CROSS Research S.A. Phase I Unit
RECRUITING

Arzo, CH-6864, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.